Dr Karine Mardon obtained her PhD in radiopharmacology from University Paris XII in 1994; she then moved to Australia to pursue postdoctoral studies at ANSTO in the Radiopharmaceutical Division and worked there for 5 years in the development and characterisation of radiopharmaceuticals for SPECT and PET. She has extensive experience with in vitro and in vivo preclinical research, particularly in the evaluation of drugs developed for the study of movement disorders as well as in the evaluation of radiolabelled peripheral benzodiazepine receptor ligands as markers of neurodegeneration and tumour occurrence. She moved to Brisbane in 2000 and joined the University of Queensland where she developed further experience working in the field of preclinical drug development in the ADME division of TetraQ. She joined the Centre for Advanced Imaging in October 2010 as NIF Facility Fellow for preclinical PET/CT.
